Ralimetinib

Drug Profile

Ralimetinib

Alternative Names: LSN-2322600; LY-2228820; LY2228820 dimesylate; p38 MAP inh; Ralimetinib mesylate

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Centre Jean Perrin; Eli Lilly
  • Class 2 ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Glioblastoma
  • Phase I Colorectal cancer; Non-small cell lung cancer
  • No development reported Lymphoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 15 May 2017 Eli Lilly completes a phase I trial in Non-small cell lung cancer and Colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Germany, USA (IV) (NCT02860780)
  • 05 Aug 2016 Eli Lilly plans a phase I trial for Cancer, including Colorectal cancer and Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA and Germany (PO) (NCT02860780)
  • 01 Aug 2016 Phase-I clinical trials in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in Germany, USA (PO) (NCT02860780)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top